Health Care [ 5/12 ] | Biotechnology [ 29/74 ]
NASDAQ | Common Stock
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States.
The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications.
Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 27, 22 | -0.05 Increased by +11.50% | - |
| Jun 8, 22 | -0.24 Decreased by -315.22% | -0.08 Decreased by -200.00% |
| Dec 1, 21 | 0.00 Increased by +100.00% | - |
| Sep 24, 21 | -0.08 Decreased by -102.02% | - |
| May 17, 21 | -0.06 Decreased by -42.68% | -0.04 Decreased by -42.68% |
| Mar 31, 21 | -0.06 Decreased by -254.60% | - |
| Dec 2, 20 | -0.04 Increased by +71.71% | -0.04 |
| Sep 30, 20 | -0.04 Increased by +67.00% | -0.01 Decreased by -296.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | N/A Decreased by N/A% | -10.88 M Decreased by N/A% | - - |
| Dec 31, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Sep 30, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Jun 30, 22 | N/A Decreased by N/A% | -4.51 M Increased by +74.18% | - - |
| Mar 31, 22 | N/A Decreased by N/A% | N/A Increased by +100.00% | - - |
| Dec 31, 21 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Sep 30, 21 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Jun 30, 21 | N/A Decreased by N/A% | -17.48 M Decreased by -252.85% | - - |